Becker's Healthcare June 25, 2024
Vutrisiran, a new drug made by Alnylam Pharmaceuticals to treat ATTR amyloidosis with cardiomyopathy, reduced the risk of death by 36% in patients, the drugmaker announced June 24.
Overall, in phase 3 trials, vutrisiran caused almost no adverse events in patients.
“[V]utrisiran has the potential to address the needs of patients with ATTR amyloidosis with cardiomyopathy, a steadily progressive, debilitating, and ultimately fatal disease,” Pushkal Garg, MD, chief medical officer of Alnylam, said in a news release. “The results showed that vutrisiran improved cardiovascular outcomes, including survival, function and...
Today's Sponsors
Today's Sponsor